ProteinLogic
ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform that detects non-obvious diagnostic patterns in soluble immune proteins in blood and other body fluids using machine learning. These patterns create unique signatures indicating disease presence, stage, and potential treatment response. The company has validated this technology with a blood-based signature for ruling out Active Tuberculosis (TB), meeting WHO criteria. ProteinLogic aims to create further value by validating other ImmiPrint® signatures for infectious, autoimmune, and inflammatory diseases. The company has received a $1.35 million grant from the Bill & Melinda Gates Foundation with Stellenbosch University to develop its TB diagnostic, and has also participated in EU Horizon 2020 projects for TB and early-stage cancer diagnosis.
ProteinLogic
ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform that detects non-obvious diagnostic patterns in soluble immune proteins in blood and other body fluids using machine learning. These patterns create unique signatures indicating disease presence, stage, and potential treatment response. The company has validated this technology with a blood-based signature for ruling out Active Tuberculosis (TB), meeting WHO criteria. ProteinLogic aims to create further value by validating other ImmiPrint® signatures for infectious, autoimmune, and inflammatory diseases. The company has received a $1.35 million grant from the Bill & Melinda Gates Foundation with Stellenbosch University to develop its TB diagnostic, and has also participated in EU Horizon 2020 projects for TB and early-stage cancer diagnosis.
TL;DR
Founded: 2003 (Cambridge, United Kingdom)
Core technology: ImmiPrint® — a machine-learning platform that detects disease-specific patterns in soluble immune proteins from blood and other body fluids
Validated asset: Blood-based ImmiPrint signature to rule out active tuberculosis (meets WHO criteria)
Recent funding: $1.35M grant from the Bill & Melinda Gates Foundation (announced 2024-01-22) with Stellenbosch University
Primarily grant / non-dilutive funding (Bill & Melinda Gates Foundation, Horizon 2020, UK Technology Strategy Board)
Company Overview
Problem Domain
Biomarker discovery and diagnostics for infectious, autoimmune and inflammatory diseases, with a focus on tuberculosis diagnosis and treatment monitoring.
Founded
2003
Industry
Biotechnology
Tech Stack
Funding Track Record
$1.35M
Collaborative grant with Stellenbosch University to develop ImmiPrint® technology for monitoring TB treatment response; described as non-dilutive funding.
Horizon 2020 funding (ADVANTAGE 666308) supported development of an Active TB rule-out test and multi-site TB clinical studies.
Grant awarded to support development activities for a Hepatitis B diagnostic test (described in a 2013 news item referencing a 2012 award date).
Investor Signal
“Primarily grant-funded / non-dilutive support from foundations and public agencies (e.g., Bill & Melinda Gates Foundation, Horizon 2020, UK Technology Strategy Board)”